Drug intelligence / Profile preview

CAR-511

Development stage: Preclinical
Lead developer: Carmel Biosciences

Overview

CAR-511 is a preclinical drug candidate developed by Carmel Biosciences, a pharmaceutical company specializing in cardiovascular and metabolic therapies. It was part of a pipeline of four preclinical candidates (CAR-509, CAR-510, CAR-511, CAR-512) that Nutriband briefly intended to acquire as part of an all-stock transaction for Carmel Biosciences. The acquisition, valued at approximately $2.7 million, was aimed at expanding Nutriband's portfolio into oral liquid drugs and cardiovascular/metabolic diseases, but the agreement was terminated in November 2018.

Beyond the preview

Go deeper on CAR-511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-511.

Explore the full profile